Eyenovia Reports Results of MicroLine in P-III Trial for the Treatment of Presbyopia
- The P-III (VISION-2) study evaluates the safety & efficacy of MicroLine vs PBO in patients (n=140) with presbyopia randomly assigned in groups receiving a 2% dosing of MicroLine vs PBO
- The results demonstrated that the study met its 1EP depicting a ≥15-letter improvement in distance corrected near visual acuity with ≤5-letter loss in distance acuity vs PBO in low light conditions @2hrs. post-treatment. The study also met all 2EPs at a statistically significant level
- MicroLine is a pilocarpine ophthalmic solution developed for the treatment of presbyopia. Additionally, Eyenovia expects to submit an NDA application for the approval of MicroLine to the US FDA within its planned commercialization timeline
Ref: GlobeNewswire | Image: Businesswire
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.